Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.73 |
| ▸ | RAB9A | P51151 | 3/20 | 0.73 |
| ▸ | CA12 | O43570 | 2/20 | 0.73 |
| ▸ | CA9 | Q16790 | 2/20 | 0.73 |
| ▸ | HPGD | P15428 | 2/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.66 |
| ▸ | MEN1 | O00255 | 2/20 | 0.63 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.59 |
| ▸ | MGLL | Q99685 | 1/20 | 0.59 |
| ▸ | CA1 | P00915 | 1/20 | 0.59 |
| ▸ | CA2 | P00918 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL11786759 | 0.98 | NPC1 (0.70) | NPC1RAB9ACA12CA9HPGD | |
| SCHEMBL3095761 | 0.88 | NPC1 (0.70) | NPC1RAB9ACA12CA9HPGD | |
| SCHEMBL967363 | 0.86 | NPC1 (0.68) | NPC1RAB9ACA12CA9HPGD | |
| SCHEMBL425164 | 0.86 | NPC1 (0.68) | NPC1RAB9ACA12CA9HPGD | |
| SCHEMBL967111 | 0.85 | NPC1 (0.66) | NPC1RAB9ACA12CA9HPGD | |
| SCHEMBL425163 | 0.85 | NPC1 (0.66) | NPC1RAB9ACA12CA9HPGD | |
| SCHEMBL9547511 | 0.85 | NPC1 (0.66) | NPC1RAB9ACA12CA9HPGD | |
| SCHEMBL11421388 | 0.85 | NPC1 (0.66) | NPC1RAB9ACA12CA9HPGD | |
| SCHEMBL967112 | 0.85 | NPC1 (0.66) | NPC1RAB9ACA12CA9HPGD | |
| SCHEMBL3369887 | 0.85 | NPC1 (0.66) | NPC1RAB9ACA12CA9HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 200 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4240484-A1 | PYRIDAZINONE DERIVATIVES AS THYROID RECEPTOR AGONISTS AND USES THEREOF | Aligos Therapeutics, Inc. (US) | 2023-09-13 | — | — | EP | claimed |
| WO-2022099049-A1 | PYRIDAZINONE DERIVATIVES AS THYROID RECEPTOR AGONISTS AND USES THEREOF | ALIGOS THERAPEUTICS, INC. (US) | 2022-05-12 | — | — | WO | claimed |
| EP-3301749-B1 | METHOD FOR PRODUCING SECONDARY BATTERY | LG CHEMICAL LTD (KR) | 2019-07-03 | — | — | EP | claimed |
| EP-2629889-B1 | RUTHENIUM COMPLEXES AND THEIR USES IN PROCESSES FOR FORMATION AND/OR HYDROGENATION OF ESTERS, AMIDES AND DERIVATIVES THEREOF | YEDA RES & DEV (IL) | 2019-04-03 | — | — | EP | claimed |
| EP-3364940-A1 | METHOD OF CHROMATOGRAPHIC SEPARATION | The Procter and Gamble Company (US) | 2018-08-29 | — | — | EP | claimed |
| WO-2017070414-A1 | METHOD OF CHROMATOGRAPHIC SEPARATION | THE PROCTER & GAMBLE COMPANY (US) | 2017-04-27 | — | — | WO | claimed |
| EP-2562171-B1 | GERMINATION-STIMULANT CARBAMATE DERIVATIVES AND PROCESS FOR PREPARATION THEREOF | NAT UNIV CORP UNIV KOBE (JP) | 2015-01-21 | — | — | EP | claimed |
| CN-101146530-B | 3, 4-substituted pyrrolidine derivatives for the treatment of hypertension | NOVARTIS AG | 2011-05-18 | — | — | CN | claimed |
| EP-1863477-B1 | 3,4-SUBSTITUTED PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF HYPERTENSION | NOVARTIS AG (CH) | 2010-11-03 | — | — | EP | claimed |
| US-7807709-B2 | Organic compounds | NOVARTIS AG (CH) | 2010-10-05 | — | — | US | claimed |
| US-20050075327-A1 | Carbamic acid alkyl ester derivatives | HOFFMAN-LA ROCHE INC. | 2005-04-07 | — | — | US | claimed |
| US-20040044205-A1 | Process for the enantiomeric enrichment of cis-8-benzyl-7,9-dioxo-2,8-diazabicyclo[4.3.0]nonane | LANXESS DEUTSCHLAND GMBH (DE) | 2004-03-04 | — | — | US | claimed |
| EP-0874809-B1 | CARBAMOYLOXY DERIVATIVES OF MUTILINE AND THEIR USE AS ANTIBACTERIALS | SMITHKLINE BEECHAM PLC (GB) | 2003-08-27 | — | — | EP | claimed |
| EP-0950056-B1 | N-(PYRIDINYLAMINO)ISOINDOLINES AND RELATED COMPOUNDS | AVENTIS PHARMA INC (US) | 2002-09-18 | — | — | EP | claimed |
| EP-0644189-B1 | Resolution of stereoisomers of aliphatic epoxides | DAICEL CHEM (JP) | 2002-01-16 | — | — | EP | claimed |
| EP-0842142-B1 | PROCESS FOR PRODUCING ALPHA-(N,N DIALKYL)-AMINO CARBOXYLIC ACID AMIDES | BASF AG (DE) | 2001-09-26 | — | — | EP | claimed |
| US-6239175-B1 | Carbamoyloxy derivatives of mutiline and their use as antibacterials | SMITHKLINE BEECHAM P.L.C. (GB) | 2001-05-29 | — | — | US | claimed |
| US-5945543-A | REACTING CORRESPONDING FREE ACIDS WITH PRIMARY OR SECONDARY AMINES IN THE PRESENCE OF ANHYDRIDES OF AN ALKANEPHOSPHONIC ACID | BASF AKTIENGESELLSCHAFT (DE) | 1999-08-31 | — | — | US | claimed |
| US-5514818-A | POLYSACCHARIDE | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 1996-05-07 | — | — | US | claimed |
| EP-0411583-B1 | AUTOGENOUSLY AIR-SETTING MORTAR | SYREMONT S.p.A. (IT) | 1993-06-16 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075327-A1 | Carbamic acid alkyl ester derivatives | BCHE, CHRM1, ADCY7 | NPC1 370/4885RAB9A 83/4885CA12 956/4885 |
| US-20040044205-A1 | Process for the enantiomeric enrichment of cis-8-benzyl-7,9-dioxo-2,8-diazabicyclo[4.3.0]nonane | CYP1B1, DECR1, SPIN2B | NPC1 2932/4885RAB9A 818/4885CA12 3143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.